Last reviewed · How we verify

LCB01-0371 800mg, BID — Competitive Intelligence Brief

LCB01-0371 800mg, BID (LCB01-0371 800mg, BID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LSD1 inhibitor. Area: Oncology.

phase 2 LSD1 inhibitor LSD1 (lysine-specific demethylase 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LCB01-0371 800mg, BID (LCB01-0371 800mg, BID) — LigaChem Biosciences, Inc.. LCB01-0371 is a selective inhibitor of lysine-specific demethylase 1 (LSD1) that restores gene expression silenced by aberrant histone methylation in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LCB01-0371 800mg, BID TARGET LCB01-0371 800mg, BID LigaChem Biosciences, Inc. phase 2 LSD1 inhibitor LSD1 (lysine-specific demethylase 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LSD1 inhibitor class)

  1. LigaChem Biosciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LCB01-0371 800mg, BID — Competitive Intelligence Brief. https://druglandscape.com/ci/lcb01-0371-800mg-bid. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: